Who is sponsoring NCT00256828?

NCT00256828 is sponsored by Clinical Trial Agency of HIV Study Group.

What condition does NCT00256828 study?

NCT00256828 studies HIV Infections.

What drugs are being tested in NCT00256828?

Interventions: didanosine + lamivudine + efavirenz.

What is the status of NCT00256828?

NCT00256828 is currently COMPLETED.

Last reviewed 2007-10-15 · How we verify

A Multicenter, Randomized, Open Label, Clinical Trial Comparing a QD Regimen of Didanosine, Lamivudine and Efavirenz With a Standard BID Regimen of Zidovudine, Lamivudine and Efavirenz in the Starting Treatment of Human Immunodeficiency Virus Infection (GESIDA 39/03)

NCT00256828 Phase 4 COMPLETED

The purpose of this study is to compare the antiviral activity of two treatment groups for HIV chronic infection: a QD regimen of didanosine, lamivudine and efavirenz versus a BID regimen of zidovudine, lamivudine and efavirenz. Both will be administered with food in the starting treatment of human immunodeficiency virus infection at Week 48.

Details

Lead sponsor	Clinical Trial Agency of HIV Study Group
Phase	Phase 4
Status	COMPLETED
Enrolment	360
Start date	2004-06
Completion	2006-11

Conditions

HIV Infections

Interventions

didanosine + lamivudine + efavirenz

Primary outcomes

Percentage of patients with HIV-RNA levels < 50 c/ml (intent-to-treat [ITT])

Countries

Spain